Contineum Therapeutics, Inc.
CTNMHealthcare|Biotechnology|US
$9.52
+0.71 (+8.06%)
DCF Value
$2.40
Tangible Book / Share
$6.39
Cash / Share
$6.37
Ownership Breakdown
85.1%
Float
35.4M
Shares Outstanding
30.1M
Float Shares
Major Holders (35)
Combined: 181.6%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| FMR LLC | Holding company | 7.90% | 2,610,247 | Nov 5, 2026 | 13D/G |
| Abigail P. Johnson | Individual | 7.90% | 2,610,247 | Nov 5, 2026 | 13D/G |
| Janus Henderson Group PLC | Holding company | 7.90% | 2,448,979 | Feb 17, 2026 | 13D/G |
| Balyasny Asset Management Holdings LP | HC, PN | 7.14% | 2,335,550 | Aug 14, 2026 | 13D/G |
| Balyasny Asset Management L.P. | IA, PN | 7.14% | 2,335,550 | Aug 14, 2026 | 13D/G |
| Dmitry Balyasny | HC, IN | 7.14% | 2,335,550 | Aug 14, 2026 | 13D/G |
| Dames GP LLC | HC, OO | 7.14% | 2,335,550 | Aug 14, 2026 | 13D/G |
| Bam GP LLC | HC, OO | 7.14% | 2,335,550 | Aug 14, 2026 | 13D/G |
| BlackRock, Inc. | Holding company | 6.30% | 2,049,493 | Jul 27, 2026 | 13D/G |
| Franklin Resources, Inc. | HC, CO | 6.20% | 1,879,367 | Jan 29, 2026 | 13D/G |
| Johnson & Johnson Innovation - JJDC, Inc. | Corporation | 5.60% | 1,979,173 | Nov 6, 2026 | 13D/G |
| Johnson & Johnson | Corporation | 5.60% | 1,979,173 | Nov 6, 2026 | 13D/G |
| Franklin Advisers, Inc. | IA, CO | 5.20% | 1,704,550 | Oct 28, 2026 | 13D/G |
| Franklin Templeton, Inc. | HC, CO | 5.20% | 1,704,550 | Oct 28, 2026 | 13D/G |
| Squadron Master Fund LP | Partnership | 5.10% | 1,700,000 | Oct 28, 2026 | 13D/G |
| Squadron Capital Management LLC | IA, HC | 5.10% | 1,700,000 | Oct 28, 2026 | 13D/G |
| Matthew Sesterhenn | HC, IN | 5.10% | 1,700,000 | Oct 28, 2026 | 13D/G |
| William Blank | HC, IN | 5.10% | 1,700,000 | Oct 28, 2026 | 13D/G |
| Trails Edge Biotechnology Master Fund, LP | Partnership | 5.10% | 1,679,443 | Oct 22, 2026 | 13D/G |
| Ortav Yehudai | Individual | 5.10% | 1,679,443 | Oct 22, 2026 | 13D/G |
| Trails Edge Capital Partners, LP | IA, PN | 5.10% | 1,679,443 | Oct 22, 2026 | 13D/G |
| Jérôme G. Pfund | Holding company | 5.00% | 950,886 | Nov 14, 2024 | 13D/G |
| Jerome G. Pfund | Holding company | 4.99% | 950,786 | Feb 14, 2025 | 13D/G |
| Sectoral Asset Management Inc | Investment adviser | 4.20% | 800,787 | Feb 14, 2025 | 13D/G |
| Sectoral Asset Management Inc. | Investment adviser | 4.20% | 800,887 | Nov 14, 2024 | 13D/G |
| RA Capital Management, L.P. | IA, PN | 4.00% | 1,296,012 | May 15, 2026 | 13D/G |
| Peter Kolchinsky | HC, IN | 4.00% | 1,296,012 | May 15, 2026 | 13D/G |
| Rajeev Shah | HC, IN | 4.00% | 1,296,012 | May 15, 2026 | 13D/G |
| RA Capital Healthcare Fund, L.P. | Partnership | 4.00% | 1,296,012 | May 15, 2026 | 13D/G |
| Perceptive Advisors LLC | Investment adviser | 3.20% | 699,486 | Aug 14, 2025 | 13D/G |
| Joseph Edelman | Individual | 3.20% | 699,486 | Aug 14, 2025 | 13D/G |
| Perceptive Life Sciences Master Fund, Ltd. | Corporation | 3.20% | 699,486 | Aug 14, 2025 | 13D/G |
| Israel A. Englander | Individual | 2.80% | 931,709 | Jul 17, 2026 | 13D/G |
| Millennium Group Management LLC | Other | 2.80% | 931,709 | Jul 17, 2026 | 13D/G |
| Millennium Management LLC | Other | 2.80% | 931,709 | Jul 17, 2026 | 13D/G |
Insider Trades (100)
Last 4 quarters: 1,392,250 acquired · 211,023 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Stengone Carmine N. | director, officer: CEO and President | Sep 8, 2026 | OPTION EX. | 2,500 | $1.01 | $2.5K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Sep 8, 2026 | OPTION EX. | 2,500 | $1.01 | $2.5K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Sep 8, 2026 | SELL | 2,500 | $16.46 | $41.1K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Aug 3, 2026 | OPTION EX. | 2,500 | $1.01 | $2.5K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Aug 3, 2026 | OPTION EX. | 2,500 | $1.01 | $2.5K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Aug 3, 2026 | SELL | 2,500 | $16.01 | $40.0K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 8, 2026 | OPTION EX. | 1,015 | $1.01 | $1.0K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 9, 2026 | OPTION EX. | 25 | $1.01 | $25.25 | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 9, 2026 | SELL | 25 | $16.00 | $400.00 | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 8, 2026 | OPTION EX. | 1,015 | $1.01 | $1.0K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 9, 2026 | OPTION EX. | 25 | $1.01 | $25.25 | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Jul 8, 2026 | OPTION EX. | 2,500 | $1.01 | $2.5K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Jul 8, 2026 | OPTION EX. | 2,500 | $1.01 | $2.5K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Jul 8, 2026 | SELL | 2,500 | $16.00 | $40.0K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jun 30, 2026 | OPTION EX. | 28,826 | $1.01 | $29.1K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 1, 2026 | OPTION EX. | 4,183 | $1.01 | $4.2K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jun 30, 2026 | SELL | 28,826 | $16.04 | $462.3K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 1, 2026 | SELL | 5,852 | $15.67 | $91.7K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 1, 2026 | SELL | 2,501 | $16.24 | $40.6K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jun 30, 2026 | OPTION EX. | 28,826 | $1.01 | $29.1K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 1, 2026 | OPTION EX. | 4,183 | $1.01 | $4.2K | Form 4 |
| Watkins Tim | CMO & Head of Development | Jun 30, 2026 | OPTION EX. | 10,833 | $4.50 | $48.7K | Form 4 |
| Watkins Tim | CMO & Head of Development | Jun 30, 2026 | OPTION EX. | 10,833 | $4.50 | $48.7K | Form 4 |
| Watkins Tim | CMO & Head of Development | Jun 30, 2026 | SELL | 10,833 | $16.02 | $173.6K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Jun 30, 2026 | OPTION EX. | 7,500 | $1.01 | $7.6K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Jun 30, 2026 | OPTION EX. | 2,500 | $1.26 | $3.1K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Jun 30, 2026 | OPTION EX. | 2,500 | $1.26 | $3.1K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Jun 30, 2026 | OPTION EX. | 7,500 | $1.01 | $7.6K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Jun 30, 2026 | SELL | 10,000 | $16.01 | $160.1K | Form 4 |
| Miralles Gines Diego | director | Jun 26, 2026 | AWARD | 19,000 | $14.19 | $269.6K | Form 4 |
| Lyons-Williams Lori | director | Jun 26, 2026 | AWARD | 19,000 | $14.19 | $269.6K | Form 4 |
| Ware Olivia C | director | Jun 26, 2026 | AWARD | 19,000 | $14.19 | $269.6K | Form 4 |
| Schimmelpennink Evert B. | director | Jun 26, 2026 | AWARD | 19,000 | $14.19 | $269.6K | Form 4 |
| Ignelzi Troy A. | director | Jun 26, 2026 | AWARD | 19,000 | $14.19 | $269.6K | Form 4 |
| Brady Todd R. | director | Jun 26, 2026 | AWARD | 19,000 | $14.19 | $269.6K | Form 4 |
| Boyce Sarah | director | Jun 26, 2026 | AWARD | 19,000 | $14.19 | $269.6K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jun 1, 2026 | SELL | 4,170 | $13.16 | $54.9K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | May 1, 2026 | SELL | 3,870 | $13.06 | $50.5K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | May 1, 2026 | SELL | 300 | $13.84 | $4.2K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Apr 6, 2026 | SELL | 4,170 | $13.43 | $56.0K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Mar 2, 2026 | SELL | 4,170 | $15.01 | $62.6K | Form 4 |
| Watkins Tim | CMO & Head of Development | Mar 2, 2026 | OPTION EX. | 3,611 | $4.50 | $16.2K | Form 4 |
| Watkins Tim | CMO & Head of Development | Mar 2, 2026 | OPTION EX. | 3,611 | $4.50 | $16.2K | Form 4 |
| Watkins Tim | CMO & Head of Development | Mar 2, 2026 | SELL | 3,611 | $15.02 | $54.2K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Feb 24, 2026 | OPTION EX. | 4,400 | $1.26 | $5.5K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Feb 25, 2026 | OPTION EX. | 2,700 | $1.26 | $3.4K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Feb 24, 2026 | OPTION EX. | 4,400 | $1.26 | $5.5K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Feb 25, 2026 | OPTION EX. | 2,700 | $1.26 | $3.4K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Feb 24, 2026 | SELL | 4,400 | $16.02 | $70.5K | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Feb 25, 2026 | SELL | 2,700 | $16.02 | $43.2K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 24, 2026 | OPTION EX. | 4,300 | $1.01 | $4.3K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 25, 2026 | OPTION EX. | 3,824 | $1.01 | $3.9K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 25, 2026 | SELL | 3,824 | $16.01 | $61.2K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 24, 2026 | SELL | 4,300 | $16.03 | $68.9K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 24, 2026 | OPTION EX. | 4,300 | $1.01 | $4.3K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 25, 2026 | OPTION EX. | 3,824 | $1.01 | $3.9K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 19, 2026 | OPTION EX. | 100 | $1.01 | $101.00 | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 19, 2026 | SELL | 100 | $16.00 | $1.6K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 19, 2026 | OPTION EX. | 100 | $1.01 | $101.00 | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Feb 11, 2026 | OPTION EX. | 400 | $1.26 | $504.00 | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Feb 11, 2026 | OPTION EX. | 400 | $1.26 | $504.00 | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Feb 11, 2026 | SELL | 400 | $16.00 | $6.4K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 11, 2026 | OPTION EX. | 400 | $1.01 | $404.00 | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 11, 2026 | SELL | 400 | $16.00 | $6.4K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 11, 2026 | OPTION EX. | 400 | $1.01 | $404.00 | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 3, 2026 | SELL | 3,000 | $14.82 | $44.5K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Feb 3, 2026 | SELL | 1,170 | $15.25 | $17.8K | Form 4 |
| Healy John Stephen | General Counsel and Corp Sec | Jan 30, 2026 | AWARD | 206,411 | $14.26 | $2.9M | Form 4 |
| Slover Peter T | Chief Financial Officer | Jan 30, 2026 | AWARD | 192,000 | $14.26 | $2.7M | Form 4 |
| Stengone Carmine N. | director, officer: CEO and President | Jan 30, 2026 | AWARD | 445,000 | $14.26 | $6.3M | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jan 30, 2026 | AWARD | 160,000 | $14.26 | $2.3M | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jan 30, 2026 | AWARD | 6,500 | $14.26 | $92.7K | Form 4 |
| Watkins Tim | CMO & Head of Development | Jan 28, 2026 | OPTION EX. | 3,611 | $4.50 | $16.2K | Form 4 |
| Watkins Tim | CMO & Head of Development | Jan 30, 2026 | AWARD | 160,000 | $14.26 | $2.3M | Form 4 |
| Watkins Tim | CMO & Head of Development | Jan 28, 2026 | OPTION EX. | 3,611 | $4.50 | $16.2K | Form 4 |
| Watkins Tim | CMO & Head of Development | Jan 28, 2026 | SELL | 2,800 | $14.09 | $39.4K | Form 4 |
| Watkins Tim | CMO & Head of Development | Jan 28, 2026 | SELL | 811 | $14.48 | $11.7K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jan 5, 2026 | SELL | 3,670 | $10.35 | $38.0K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jan 5, 2026 | SELL | 500 | $11.13 | $5.6K | Form 4 |
| Watkins Tim | CMO & Head of Development | Dec 29, 2025 | OPTION EX. | 3,611 | $4.50 | $16.2K | Form 4 |
| Watkins Tim | CMO & Head of Development | Dec 29, 2025 | OPTION EX. | 3,611 | $4.50 | $16.2K | Form 4 |
| Watkins Tim | CMO & Head of Development | Dec 29, 2025 | SELL | 3,611 | $12.06 | $43.6K | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Dec 23, 2025 | SELL | 4,170 | $12.23 | $51.0K | Form 4 |
| Boyce Sarah | director | Jun 26, 2025 | AWARD | 14,750 | $4.01 | $59.1K | Form 4 |
| Schimmelpennink Evert B. | director | Jun 26, 2025 | AWARD | 14,750 | $4.01 | $59.1K | Form 4 |
| Brady Todd R. | director | Jun 26, 2025 | AWARD | 14,750 | $4.01 | $59.1K | Form 4 |
| Ignelzi Troy A. | director | Jun 26, 2025 | AWARD | 14,750 | $4.01 | $59.1K | Form 4 |
| Lyons-Williams Lori | director | Jun 26, 2025 | AWARD | 14,750 | $4.01 | $59.1K | Form 4 |
| Ware Olivia C | director | Jun 26, 2025 | AWARD | 14,750 | $4.01 | $59.1K | Form 4 |
| Miralles Gines Diego | director | Jun 26, 2025 | AWARD | 14,750 | $4.01 | $59.1K | Form 4 |
| Watkins Tim | CMO & Head of Development | Apr 28, 2025 | AWARD | 260,000 | $4.50 | $1.2M | Form 4 |
| Watkins Tim | CMO & Head of Development | Apr 28, 2025 | AWARD | 26,000 | $4.50 | $117.0K | Form 4 |
| Watkins Tim | officer | Apr 28, 2025 | OTHER | 0 | — | — | Form 4 |
| Miralles Gines Diego | director | Mar 14, 2025 | AWARD | 29,500 | $6.67 | $196.8K | Form 4 |
| Miralles Gines Diego | director | Mar 14, 2025 | OTHER | 5,000 | $17.92 | $89.6K | Form 4 |
| Healy John Stephen | General Counsel and Corp Sec | Jan 31, 2025 | AWARD | 63,589 | $9.79 | $622.5K | Form 4 |
| Slover Peter T | Chief Financial Officer | Jan 31, 2025 | AWARD | 110,000 | $9.79 | $1.1M | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jan 31, 2025 | AWARD | 110,000 | $9.79 | $1.1M | Form 4 |
| Lorrain Daniel S. | Chief Scientific Officer | Jan 31, 2025 | AWARD | 3,700 | $9.79 | $36.2K | Form 4 |
| Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | Jan 31, 2025 | AWARD | 110,000 | $9.79 | $1.1M | Form 4 |